These findings indicate that FGF21 acts on cardiomyocytes possibly in a paracrine manner and prevents cardiac hypertrophy by activating MAPK signaling through the activation of FGFR1c with β-Klotho (Table 1) (Planavila et al., 2013). The gene discussed is FGF21; the disease is cardiac hypertrophy.